

PROGRAM

Day 1: October 23

- 7:45. a.m. - 5:30 p.m. **Registration**
- 8:00 a.m. - 8:30 a.m. **Day 1 Poster Setup**
Travel Awardee Posters will stay up for the entire meeting.
- 8:30 a.m. - 8:45 a.m. **Opening Remarks**
Geraldina Dominguez, Ph.D.
National Cancer Institute, NIH
- 8:45 a.m. - 9:00 a.m. **Welcome**
Robert Yarchoan, M.D.
National Cancer Institute, NIH
- 9:00 a.m. - 10:30 a.m. **Session 1: HPV and Cervical Cancer**
Moderators: Joel Palefsky, M.D.
University of California, San Francisco

Mark H. Einstein, M.D.
Rutgers University
- 9:00 a.m. - 9:30 a.m. ***P1. HPV/Vaccine Trial***
Douglas R. Lowy, M.D.
National Cancer Institute, NIH
- 9:30 a.m. - 10:00 a.m. ***P2. Cervical Cancer Control in Africa***
Hennie Botha, MBChB, M.Med, FCOG, Ph.D.
Stellenbosch University
- 10:00 a.m. - 10:30 a.m. ***P3. Molecular Carcinogenesis of Cervical Cancer: Beyond HPV***
Nicolas Wentzensen, M.D., Ph.D.
National Cancer Institute, NIH
- 10:30 a.m. - 11:00 a.m. **Break and Poster Viewing**
- 11:00 a.m. - 12 noon **Session 2: Gene Therapy and Stem Cell Transplantation**
Moderator: Thomas S. Uldrick, M.D.
National Cancer Institute, NIH
- 11:00 a.m. - 11:30 a.m. ***P4. HIV Gene Therapy***
Hans-Peter Kiem, M.D., Ph.D.
Fred Hutchinson Cancer Research Center
- 11:30 a.m. - 12 noon ***P5. Hematopoietic Transplantation for Patients With HIV and Hematologic Malignancies***
Richard F. Ambinder, M.D., Ph.D.
Johns Hopkins University School of Medicine
- 12 noon - 1:00 p.m. **Lunch** (on your own or lunch boxes)

- 1:00 p.m. - 2:00 p.m. **Day 1 Poster Viewing** (Presenters stand by their posters.)
- 2:00 p.m. - 3:00 p.m. **Session 3: Epstein-Barr Virus and Rhesus Rhadinovirus**
Moderators: Ethel Cesarman, M.D., Ph.D.
Weill Cornell Medical College
- Erle S. Robertson, Ph.D.
Perelman School of Medicine, University of Pennsylvania
- 2:00 p.m. - 2:15 p.m. ***O1. Development of an EBNA1 Inhibitor for the Treatment of HIV-Associated Epstein-Barr Virus-Driven Malignancies***
Troy E. Messick, Ph.D.
The Wistar Institute
- 2:15 p.m. - 2:30 p.m. ***O2. Tumor Epstein-Barr Virus Status Is Prognostic in Primary Effusion Lymphoma***
Kathryn Lurain, M.D.
National Cancer Institute, NIH
- 2:30 p.m. - 2:45 p.m. ***O3. Cell Receptor Activation Triggers Caspase-Mediated Cleavage of PIAS1 to Facilitate Epstein-Barr Virus Lytic Replication***
Renfeng Li, Ph.D.
Philips Institute for Oral Health Research
- 2:45 p.m. - 3:00 p.m. ***O4. Anti-IL-15-Mediated Depletion of NK Cells in Primary SIV Infection Does Not Alter SIV Replication but Accelerates Rhesus Rhadinovirus Pathogenesis***
Afam A. Okoye, Ph.D.
Oregon Health & Science University
- 3:00 p.m. - 3:30 p.m. **Break and Poster Viewing**
- 3:30 p.m. - 5:45 p.m. **Session 4: KSHV and Kaposi Sarcoma**
Moderators: Dirk Dittmer, Ph.D.
The University of North Carolina at Chapel Hill
- Paul M. Lieberman, Ph.D.
The Wistar Institute
- 3:30 p.m. - 4:00 p.m. ***P6. KSHV Targets Nuclear Export of mRNA to Regulate Host Gene Expression***
Ting-Ting Wu, Ph.D.
University of California, Los Angeles
- 4:00 p.m. - 4:15 p.m. ***O5. Manipulation of the Host Iron Regulon by Kaposi Sarcoma Herpesvirus (KSHV)***
Ashlee V. Moses, Ph.D.
Oregon Health & Science University
- 4:15 p.m. - 4:30 p.m. ***O6. Modulation of Cholesterol Pathway in KSHV Infection***
Anna Serquiña, M.D., Ph.D.
National Cancer Institute, NIH

- 4:30 p.m. - 4:45 p.m. ***O7. Portable Nucleic Acid Amplification Testing as a Means for Diagnosis of Kaposi Sarcoma in Africa***
 Jeffrey N. Martin, M.D., M.P.H.
 University of California, San Francisco
- 4:45 p.m. - 5:00 p.m. ***O8* Kaposi Sarcoma-Associated Herpesvirus (KSHV) Seroprevalence and Antibody Levels in Relation to Haemoglobin and Malaria Among Individuals From Rural Uganda***
 Angela Nalwoga, M.Sc. (Ph.D. candidate)
 MRC/UVRI Uganda Research Unit on AIDS
- 5:00 p.m. - 5:15 p.m. ***O9. T-cell Receptor Sequencing of Tumor-Infiltrating Lymphocytes in Kaposi Sarcoma Tumors Identifies Candidate Tumor-Reactive T-cell Responses***
 Warren Phipps, M.D., M.P.H.
 Fred Hutchinson Cancer Research Center
- 5:15 p.m. - 5:30 p.m. ***O10. Exploring the Function and Mechanism of Pomalidomide-Induced Increases in Immune Surface Markers in Primary Effusion Lymphoma Cells***
 David A. Davis, Ph.D.
 National Cancer Institute, NIH
- 5:30 p.m. - 5:45 p.m. ***O11. AMC-070: Lenalidomide Is Safe and Effective in AIDS-Associated Kaposi Sarcoma***
 Dirk Dittmer, Ph.D.
 The University of North Carolina at Chapel Hill

5:45 p.m. **End of Day 1**

08* is a travel awardee.

Day 2: October 24

- 8:00 a.m. - 8:15 a.m. **Day 2 Poster Setup and Viewing**
- 8:15 a.m. - 8:30 a.m. **Welcome Day 2**
Geraldina Dominguez, Ph.D.
National Cancer Institute, NIH
- 8:30 a.m. - 10:00 a.m. **Session 5: Clinical Research and Trials**
Moderators: Lee Ratner, M.D., Ph.D.
Washington University School of Medicine in St. Louis

Richard F. Little, M.D.
National Cancer Institute, NIH
- 8:30 a.m. - 9:00 a.m. ***P7. Development of HIV-Specific T-Cell Therapy: Lessons From Epstein-Barr Virus***
Catherine Bollard, MBChB
Children's Research Institute
- 9:00 a.m. - 9:30 a.m. ***P8. As-Needed Versus Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild or Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067***
Thomas Campbell, M.D., Ph.D.
University of Colorado
- 9:30 a.m. - 9:45 a.m. ***O12. Cisplatin and Radiation Therapy in HIV-Infected Women With Locally Advanced Cervical Cancer in Sub-Saharan Africa (AMC-081)***
Mark H. Einstein, M.D., M.S.
Rutgers New Jersey Medical School
- 9:45 a.m. - 10:00 a.m. ***O13. Extracellular Vesicles Derived From HIV-Infected T Cells Promote Progression of Non-AIDS-Defining Cancers***
Ge Jin, Ph.D.
Case Western Reserve University
- 10:00 a.m. - 10:30 a.m. **Break and Poster Viewing**
- 10:30 a.m. - 12 noon **Session 6: Epidemiology and Screening**
Moderators: Gypsyamber D'Souza, Ph.D.
Johns Hopkins Bloomberg School of Public Health

Elizabeth Chiao, M.D., M.P.H.
Baylor College of Medicine
- 10:30 a.m. - 11:00 a.m. ***P9. Projected Cancer Incidence and Burden in HIV-Infected Adults in the United States Through 2030***
Meredith S. Shiels, Ph.D.
National Cancer Institute, NIH

- 11:00 a.m. - 11:15 a.m. ***O14. Elevated Risk of First and Second Primary Cancers Among People With HIV***
Nancy A. Hessol, M.S.P.H.
University of California, San Francisco
- 11:15 a.m. - 11:30 a.m. ***O15. Lung Cancer Mortality Among People Living With HIV in the United States: Impact of Smoking and Smoking Cessation***
Krishna P. Reddy, M.D.
Massachusetts General Hospital
- 11:30 a.m. - 11:45 a.m. ***O16. Prevention and Early Detection of Cervical Cancer in Africa Through Community-Based Self-Administered Screening and Mobile Treatment Provision***
Miriam Nakalembe, MBChB, Ph.D.
Infectious Diseases Institute, Makerere University
- 11:45 a.m. - 12 noon ***O17. Persistent Anal HPV16/18 Infections as Predictors of High-Grade Anal Lesions in Older MSM***
Hilary K. Hsu, M.P.H.
University of California, Los Angeles
- 12 noon - 1:00 p.m. **Lunch** (on your own or lunch boxes)
- 1:00 p.m. - 2:00 p.m. **Day 2 Poster Viewing** (Presenters stand by their posters.)
- 2:00 p.m. - 3:30 p.m. **Session 7: Polyomaviruses and Immunotherapy**
Moderators: Thomas G. Gross, M.D., Ph.D.
National Cancer Institute, NIH

Corey Casper, M.D., M.P.H.
Fred Hutchinson Cancer Research Center
- 2:00 p.m. - 2:30 p.m. ***P10. BK Polyomavirus, APOBEC3B, and Cancer: Molecular Judo Gone Awry?***
Christopher Buck, Ph.D.
National Cancer Institute, NIH
- 2:30 p.m. - 3:00 p.m. ***P11. PD-L1 Inhibition and the Evolving Management of Merkel Cell Carcinoma***
Isaac F. Brownell, M.D., Ph.D.
National Cancer Institute, NIH
- 3:00 p.m. - 3:15 p.m. ***O18*. A Case Series of Nivolumab in Veterans With HIV Infection and Malignancy***
Elaine Chang, M.D.
Baylor College of Medicine
- 3:15 p.m. - 3:30 p.m. ***O19. AMS095: A Phase I Study of Ipilimumab (Ipi) and Nivolumab (Nivo) in Advanced HIV-Associated Solid Tumors (Preliminary Findings)***
Lakshmi N. Rajdev, M.D.
Albert Einstein College of Medicine and Montefiore Medical Center
- 3:30 p.m. - 4:00 p.m. **Break and Poster Viewing**

4:00 p.m. - 5:25 p.m.

Session 8: Pathogen Host Interactions

Moderators: Jennifer Webster-Cyriaque, Ph.D., D.D.S.
The University of North Carolina at Chapel Hill

Otoniel Martinez-Maza, Ph.D.
University of California, Los Angeles

4:00 p.m. - 4:20 p.m.

P12. Epstein-Barr Virus and Malaria Profiles in African Burkitt Lymphoma: What Can We Learn From Array-Based Studies?

Sam Mbulaiteye, M.D.
National Cancer Institute, NIH

4:20 p.m. - 4:35 p.m.

O20. A Prospective Study of Serum Microbial Translocation and Inflammation-Associated Biomarkers and Risk of AIDS-Related Non-Hodgkin Lymphoma

Marta Epeldegui, Ph.D.
University of California, Los Angeles

4:35 p.m. - 4:50 p.m.

O21. Identifying Transcriptional and Prognostic Biomarkers of HIV-Associated Diffuse Large B-cell Lymphoma From Malawi

Yuri Fedoriw, M.D.
The University of North Carolina at Chapel Hill

4:50 p.m. - 5:10 p.m.

P13. KSHV and Co-infections

Denise Whitby, Ph.D.
Frederick National Laboratory for Cancer Research, NIH

5:10 p.m. - 5:25 p.m.

O22. Strategies to Improve Kaposi Sarcoma Outcomes in Zimbabwe: A Community-Based Clinical Trial of a Training Intervention for Improved Primary Care of AIDS-KS (SIKO study)

Margaret Borok, M.D.
University of Zimbabwe College of Health Sciences

5:25 p.m. - 5:35 p.m.

Closing Comments

Robert Yarchoan, M.D.
National Cancer Institute, NIH

5:35 p.m.

Meeting Adjourned

019* is a travel awardee.